Pathstone Holdings’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Pathstone Holdings’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,380	Closed	-$1.63M	–	2361
2025 Q1	$1.63M	Sell	12,380 -118	-0.9%	-$14.7K	0.01%	1100
2024 Q4	$1.04M	Buy	12,498 +25	+0.2%	+$2.05K	﹤0.01%	1349
2024 Q3	$913K	Buy	12,473 +207	+2%	+$15.6K	﹤0.01%	1416
2024 Q2	$840K	Buy	12,266 +587	+5%	+$40.7K	﹤0.01%	1420
2024 Q1	$808K	Buy	11,679 +4,996	+75%	+$343K	﹤0.01%	1419
2023 Q4	$479K	Buy	+6,683	New	+$384K	﹤0.01%	1529

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Pathstone Holdings's ITCI Position: Q2 2025 in Review

Pathstone Holdings sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 12,380 shares — an estimated $1.63M sold.

Pathstone Holdings first reported a position in ITCI in Q4 2023 and held it in 6 quarters. The position peaked at $1.63M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Pathstone Holdings reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Pathstone Holdings sold 12,380 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.63M.
Pathstone Holdings first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 6 quarters.
Pathstone Holdings's Intra-Cellular Therapies Inc. position peaked at $1.63M in Q1 2025.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Pathstone Holdings's 13F filing for Q2 2025, filed 12 Aug 2025.